MedTrace Logo

Oral Nicorandil in ST Elevation Myocardial Infarction Patients Undergoing Primary Percutaneous Coronary Intervention

NCT04632121 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2021-01-05

No results posted yet for this study

Summary

* To study the effects of early oral administration of nicorandil in the setting of PPCI among STEMI patients on early angiographic, electrocardiographic, echocardiographic and hard clinical outcomes.
* To assess the possible benefits of nicorandil on myocardial reperfusion through LGE- CMR substudy after 3 months.

Conditions

  • Nicorandil

Interventions

DRUG

Nicorandil 20 MG

Nicorandil is a nicotinamide ester that dilates peripheral and coronary resistance vessels via action on ATP-sensitive potassium channels and possesses a nitrate moiety that promotes systemic venous and coronary vasodilation. As a result of these dual actions, nicorandil reduces preload and afterload and results in an increase in coronary blood flow. In addition to these effects, nicorandil may have cardioprotective actions mediated through the activation of potassium channel

Sponsors & Collaborators

  • Ahmed Abdel Nasser Abdel Rady

    lead OTHER

Eligibility

Min Age
16 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-01
Primary Completion
2022-12-01
Completion
2023-12-29
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04632121 on ClinicalTrials.gov